interim clinical trial data PRM-151 Phase 2 myelofibrosis of Promedior to present at the 19th EHA Congress -
Promedior, Inc., a clinical stage biotechnology company development of new therapies for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present preliminary data from the ongoing Phase 2 clinical trial of the Company's lead product candidate, PRM-151 for the treatment of myelofibrosis in a poster presentation June 14, 2014 at 19 e Congress of the European hematology Association (EHA) to be held in Milan, Italy, from June 12-15, 2014. the reported data include 24 weeks results in patients with myelofibrosis and evaluate the main clinical measures of efficacy and safety related to myelofibrosis.
With a novel mechanism of action that is targeted to prevent and reverse fibrosis, PRM-151 has the potential to treat the underlying fibrotic pathology of myelofibrosis. This Phase 2 clinical trial is a multi-center, two-stage, adaptive design study to determine the efficacy and safety of PRM-151 as monotherapy or added to a stable dose of ruxolitinib in patients with primary myelofibrosis of (MFP), post-Polycythemia Vera MF (post-PV MF), or post-Essential thrombocythemia MF (post-aND MF).
EmoticonEmoticon